Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1899MR)

This product GTTS-WQ1899MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1899MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13730MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ12638MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ4061MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ9243MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ2413MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ154MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ15994MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ5820MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW